JOSEPH JANKOVIC to Blepharospasm
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Blepharospasm.
Connection Strength
4.941
-
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na?ve subjects. Curr Med Res Opin. 2021 10; 37(10):1761-1768.
Score: 0.720
-
Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
Score: 0.517
-
F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013 Jan; 70(1):20-4.
Score: 0.395
-
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
Score: 0.351
-
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
Score: 0.319
-
Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
Score: 0.302
-
Disease-oriented approach to botulinum toxin use. Toxicon. 2009 Oct; 54(5):614-23.
Score: 0.298
-
Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna). 2008; 115(4):585-91.
Score: 0.269
-
Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
Score: 0.226
-
Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis. Parkinsonism Relat Disord. 2022 11; 104:94-98.
Score: 0.195
-
Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
Score: 0.180
-
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 05 10; 86(19):1818-26.
Score: 0.124
-
IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
Score: 0.110
-
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
Score: 0.101
-
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
Score: 0.100
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.099
-
Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008 Oct 14; 71(16):1275-82.
Score: 0.074
-
Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988; 50:583-91.
Score: 0.070
-
Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49:103-16.
Score: 0.070
-
Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988; 49:467-72.
Score: 0.070
-
The other Babinski sign in hemifacial spasm. Neurology. 2007 Jul 24; 69(4):402-4.
Score: 0.068
-
Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3):159-63.
Score: 0.065
-
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
Score: 0.057
-
Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004; 94:275-86.
Score: 0.053
-
Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
Score: 0.039
-
Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
Score: 0.027
-
Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991; 6(3):248-52.
Score: 0.022
-
Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990; 53:293-304.
Score: 0.020